The article ‘Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity’ has recently been published on Nature Communications. SOM0226 (tolcapone) is a strong candidate for therapeutic intervention in the TTR Amyloidosis variants, including those affecting the central nervous system, for which no small-molecule therapy exists.

Several institutions have taken part on this research as SOM Biotech, Autonomous University of Barcelona,The Scripps Research Institute and University of Porto.

To have access to the full article, please visit  Nature Communications